1160949-99-4 Usage
General Description
3-Bromoquinolin-7-ol is a chemical compound with the molecular formula C9H6BrNO. It is a brominated derivative of quinolin-7-ol, and it contains a bromine atom attached to the carbon at the 3-position of the quinoline ring. 3-BroMoquinolin-7-ol has been used in various chemical and pharmaceutical applications due to its unique structural properties. It has been investigated for its potential use as an intermediate in organic synthesis and as a building block for the production of other chemical compounds. Additionally, 3-Bromoquinolin-7-ol has also been studied for its potential biological activities and pharmacological properties, although further research is needed to fully understand its potential applications in these areas.
Check Digit Verification of cas no
The CAS Registry Mumber 1160949-99-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,6,0,9,4 and 9 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1160949-99:
(9*1)+(8*1)+(7*6)+(6*0)+(5*9)+(4*4)+(3*9)+(2*9)+(1*9)=174
174 % 10 = 4
So 1160949-99-4 is a valid CAS Registry Number.
1160949-99-4Relevant articles and documents
NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF
-
Paragraph 0828; 0829, (2018/09/08)
An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl g roup, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R 3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R 4 and R 5 e ach independently represent a hydrogen atom; and R 2 and R 4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.
